Poster
1 A regional comparison of the mode of HIV-1 transmission in patients enrolled in the EuroSIDA study. J Tverland, J Reekie, M Paulsen, A Mocroft, A Vassilenko, V Uzdaviniene, N Zakharova, N Chentcova, M Ellefson, O Kirk for EuroSIDA. Poster 72 KB
7th European Drug Resistance Workshop, Stockholm, March 2009
Poster
1 Predictors of having a resistance test following at least one episode of viral load (VL) failure of cART: data from EuroSIDA. ZV Fox, AN Phillips, A Cozzi-Lepri, A d'Arminio Monforte, A Karlsson, A Mocroft, G Kronborg, J Kjaer, B Clotet and JD Lundgren for EuroSIDA.
Poster 191 KB
16th Conference on Retroviruses and Opportunistic Infections, Montreal, February 2009
Oral Presentations
1Risk of myocardial infarction (MI) in those exposed to specific antiretroviral drugs (ARVs) from the protease (PI), non-nucleoside reverse transcriptase (NNRTI) and nucleos(t)ide reverse transcriptase inhibitor (NRTI) drug classes: the D:A:D Study. JD Lundgren, P Reiss, S W Worm, W El-Sadr, S DeWit, R Weber, A d'Arminio Monforte, O Kirk, E Fontas, F Dabis, M G Law, N Friis-Møller, A N Phillips, C Sabin, on behalf of the D:A:D study group.
Presentation 115 KB
2 High hepatitis C viremia is associated with an increased risk for mortality in HIV/Hepatitis C virus coinfected individuals. J Rockstroh, L Peters, V Soriano, P Reiss, A d'Arminio Monforte, M Beniowski, M Losso, O Kirk, B Kupfer, A Mocroft on behalf of the EuroSIDA Study Group. Oral 111 KB
3 Association between modifiable and non-modifiable risk factors and specific causes of death in the HAART era: Results from the D:A:D study. C Smith, R Weber, S Worm, A Phillips, R Thiebaut, N Friis-Møller, C Pradier, O Kirk, A d'Arminio Monforte, W El Sadr, P Reiss, J Lundgren, C Sabin on behalf of the D:A:D Study Group.Presentation 113 KB
4 Effect of Interleukin-2 on Clinical Outcomes in Patients with a CD4+ Cell Count of 300/mm3: Primary Results of the ESPRIT Study. Marcelo Losso. Oral
5 Effect of Interleukin-2 on Clinical Outcomes in Patients with CD4+ Cell Count 50 to 299/mm3: Primary Results of the SILCAAT Study. Yves Levy and SILCAAT Sci Committee. Oral
Posters
1 Hyaluronic Acid as a Prognostic Marker of Hepatic Coma and Liver-related Death in HIV/Viral Hepatitis Coinfected Patients. L Peters, A Mocroft, V Soriano, J Rockstroh, B Ledergerber, A Karlsson, B Knysz, C Pradier, K Zimler, JD Lundgren for the EuroSIDA study group.
Poster 139 KB
2 Mutation A376S in the RT connection domain is associated with an increased risk of virological failure to nevirapine- based therapy in NNRTI-naïve HIV-infected subjects in the EuroSIDA Study. R Parades, W Bannister, A Cozzi-Lepri, C Pou, R Bellido, J Bogner, P Gargalianos, D Bánhegyi, B Clotet, JD Lundgren and the EuroSIDA study group.
Poster 247 KB
3 Serious Fatal and Non Fatal Non-AIDS Defining Illnesses (non-ADI) in Europe. A. Mocroft, P Reiss, J Gasiorowski, B Ledergerber, A Chiesi, J Gatell, A Rakhmanova, MA Johnson, O Kirk, JD Lundgren for the EuroSIDA study group.
Poster 93 KB
4 Relationship between Current Level of Immunodeficiency and Non-AIDS malignancies. J Reekie, A Mocroft, F Engsis, A d'Arminio Monforte, A Wiercinska-Drapalo, P Domingo, F Antunes, N Clumeck, O Kirk, JD Lundgren for the EuroSIDA study group.
Poster 111 KB
5 Interruption of Antiretroviral Therapy and Changes in Hyaluronic Acid as Marker of Liver Fibrosis Progression in SMART Viral Hepatitis Coinfected Participants and Matched Controls. L Peters, J Neuhaus, A Mocroft, V Soriano, J Rockstroh, G Dore, M Puoti, E Tedaldi, B Clotet, B Kupfer, JD Lundgren, MB Klein for the INSIGHT SMART Study Group.
Poster 337 KB
6 Risk of extensive triple class virologic failure of the three original antiretroviral drug classes among people followed from therapy initiation with NNRTI or ritonavir-boosted PI regimens. R Lodwick on behalf of the PLATO II project team of COHERE.
Poster 159 KB
7 Impact of cART on Incidence and Prognosis of HIV-1-associated Non-Hodgkin-Lymphoma - European Multi-Cohort Study. J Bohlius, M Egger, on behalf of the COHERE study group.
Poster 517 KB
8 Antiretroviral Therapy (ART) Reinitiation and Hepatitis B Virus (HBV) Rebound among HIV – HBV Coinfected Patients following ART interruption in the SMART Study. V. Soriano. Poster
9 Does Treatment Interruption within the SMART trial lead to changes in hepatitis C virus load in HIV-/HCV-coinfected patients? J Rockstroh. Poster
10 Does Activation of Inflammatory and Coagulation Pathways Independently Predict the Development of Opportunistic Disease in Patients with HIV Infection? A Rodger. Poster
2008
The 9th International Congress on Drug Therapy in HIV Infection, Glasgow, November 2008
Oral presentations
1 Patterns of prior viral suppression on cART as predictors of future risk of viral rebound. J Reekie, A Mocroft, B Ledergerber, M Beniowski, B Clotet, J van Lunzen, A Chiesi, C Pradier, L Machala, JD Lundgren
Poster 90 KB
2 Opportunistic infections in immunocompromised but virologically suppressed HIV-1 infected patients. W Bannister, A Mocroft, O Kirk, P Reiss, A d´Arminio-Monforte, J Gatell, M Fischer, H Trocha, A Rakhmanova, and JD Lundgren.
Poster 110 KB
3 The rate of change of CD4 count (CD4 slopes) in patients with stable HIV viremia currently taking combination antiretroviral therapy or off all antiretrovirals. A Mocroft, AN Phillips, B Ledergerber, J Bogner, K Lacombe, A Wiercinska-Drapalo, P Reiss, O Kirk, JD Lundgren for the EuroSIDA study group.
Poster 99 KB
4 Predicting the short term risk of diabetes in HIV infected patients in the D:A:D cohort: The D:A:D study group. K Petoumenos, E Fontas, SW Worm, R Weber, S De Wit, M Bruyand, CA Sabin, P Reiss, W El-Sadr, A D´Arminio-Monforte, N Friis-Møller, JD Lundgren, M Law on behalf of the D:A:D study group.
Poster 152 KB
5 The relationship between an adverse effect of antiretroviral treatment and underlying risk in number needed to treat to harm - risk of myocardial infarction and abacavir use. J Kowalska, O Kirk, A Mocroft, L Høj, N Friis-Møller, P Reiss, JD Lundgren
Poster 249 KB
6 Poor clinical oputcome in HIV-infected patients coinfected with mycobacterium tuberculosis (TB) in Eastern Europe. The HIV/TB collaborative study. D Podlekareva, A Mocroft, F Post, V Riekstina, J Miro, H Furrer, M Bruyand, E Malashenkov, E Girardi, JJ Toibaro, J Cayla, R Miller, N Obel, A Skrahin, N Chentsova, JD Lundgren, O Kirk and the HIV/TB study group.
Poster 251 KB
Poster presentation
1 Are non-B subtypes less susceptible to antiretroviral drugs? - a bioinformatical approach to prediction on non-B subtype susceptibility. J Kjær, L Høj, N Friis-Møller, P Reiss, JD Lundgren
Poster 249 KB
XVII International AIDS Conference, Mexico City, August 2008
Oral presentations
1 Use of nucleos(t)ide reverse transcriptase inhibitors (NRTIs) and risk of myocardial infarction in HIV-infected patients enrolled in the SMART study. JD Lundgren and the SMART/INSIGHT and D:A:D Study Groups.
Slides 127 KB
2 TB and injecting drug use in Eastern Europe Clinical and Epidemiological Aspects and Implications for Public Health. D. Podlekareva
Slides 716 KB
Polish National Conference on HIV, Warsaw, June 2008
1 Risk of myocardial infarction attributable to abacavir: Analysis to assess the number needed to treat to harm. Justyna D. Kowalska, Ole Kirk, Amanda Mocroft, Jens D. Lundgren
Poster 239 KB
XVII International HIV Drug Resistance Workshop, Sitges, June 2008
Poster presentations
1 In silico identification of physiochemical properties at mutating positions relevant to reduced susceptibility to amprenavir. L Høj, J Kjær, O Winther, A Cozzi-Lepri and JD Lundgren.
Poster No.113 104 KB
2 The rate of accumulation of NNRTI-resistance in patients kept on a virologically failing regimen containing NNRTI: a EuroSIDA Study. A Cozzi-Lepri, B Clotet, R Paredes, J Kjær, AN Phillips, and JD Lundgren for the EuroSIDA study group.
Poster No.128 154 KB
3 Treatment-ermergent gag cleavage site mutations during virological failure of ritonavir-boosted protease-inhibitors. A Garcia- Diaz, Z Fox, UB Dragsted, J Kjær, N Clumeck, A Phillips, JD Lundgren and AM Geretti.
Poster 73
15th Conference on Retroviruses and Opportunistic Infections, Boston, February 2008
Poster presentations
1 The use and response to second combination antiretroviral therapy (cART) regimens in EuroSIDA. A Cozzi-Lepri, M Cunnington, A Lazzarin, B Clotet, B Knysz, P Gargalianos, C Katlama, A Karlsson, AN Phillips, J D Lundgren
Poster No. 797 129 KB
2 What frequency of monitoring is needed for health-care in a HIV-infected person?J Reekie, B Gazzard, H Sambatakou, A Chiesi, J van Lunzen, N Clumeck, O Kirk, A Mocroft, L Machala, J Lundgren
Poster No. 808 104 KB
3 Indicators of the use of health care interventions across Europe. D Podlekareva, J Reekie, A Rakhmanova, A Horban, A Mocroft, I Karpov, P Domingo, F Antunes, O Kirk, JD Lundgren and the EuroSIDA study group
Poster No. 811 157 KB
4 Do Thymidine Analogues, Abacavir, Didanosine and Lamivudine Contribute to the Risk of Myocardial Infarction (MI)?
Recent Use of Abacavir and Didanosine, but not of Thymidine Analogues, Is Associated with Risk of Myocardial Infarction. Writing group: CA Sabin, SW Worm, R Weber, P Reiss, W El-Sadr, R Thiebaut, S De Wit, M Law, A D’Arminio Monforte, N Friis-Møller, O Kirk, C Pradier, S Collins, I Weller, AN Phillips, JD Lundgren on behalf of the D:A:D study group
Poster No. 957c 121 KB
5 Deterioration of renal function (DRF) associated with current level of immunodeficiency. O Kirk, A Mocroft, A d’Armino Monforte, A-BE Hansen, JM Gatell, S Caplinskas, G Fätkenheuer, P Reiss, E Vinogradova, JD Lundgren for the EuroSIDA study group.
Poster No. 971 133 KB
6 Characteristics and clinical outcome of patients with HIV-associated tuberculosis (HIV/TB) in Europe and Argentina. D Podlekareva, A Mocroft, A Panteleev, J Toibaro, A Rakhmanova, V Riekstina, H-J Furrer, O Suetnov, F Post, O Kirk and the HIV/TB Study Group
Poster No. 1000 197 KB
7 Hepatitis C virus (HCV) coinfection does not influence the CD4 cell recovery in HIV infected patients with maximum virologic suppression within the EuroSIDA cohort. L Peters, A Mocroft, V Soriano, J Rockstroh, P Aldins, M Losso, L Valerio, P Reiss, B Ledergerber, JD Lundgren for the EuroSIDA study group.
Poster No. 1069 102 KB
8 Hepatitis Virus Co-infections and Risk of Diabetes Mellitus (DM) and Myocardial Infarction (MI) in HIV-infected Persons: The D:A:D Study.R Weber, C Sabin, P Reiss, S De Wit, S Worm, M Law, F Dabis, A d'Arminio Monforte, E Fontas, J Lundgren
Poster No. 1082 82 KB
Oral presentations
1 Re-initiation of antiretroviral therapy (ART) in the CD4-guided ART interruption group in the SMART study lowers risk of opportunistic disease or death. W El-Sadr and the SMART study group
Abstract No. 36
2 Elevated levels of interleukin-6 and D-dimer are associated with an increased risk of death in patients with HIV. L Kuller and the SMART study group
Abstract No. 139
3 Age/sex-specific death rates in ART naïve patients with CD4 count above 350 cells/mm3 compared with the general population. R Lodwick, K Porter, C Sabin, B Ledergerber, A Cozzi-Lepri, P Khaykin, A Mocroft, L Jacobson, S de Wit, A Phillips on behalf of the Study Group on Death Rates at High CD4 Count in Antiretroviral Naive Patients
Abstract No.141
2007
11th European AIDS Conference (EACS), Madrid, October 2007
Posters
1 Diminished susceptibility to didanosine due to 184I/Vand thymidine analog mutations in isolates without major IAS-USA didanosine-specific and cross-resistant mutations.
J Kjær, A Cozzi-Lepri, Z Fox, and JD Lundgren
Poster P3.2/04 as pdf file 97 kb
2 Concordance between genotypic interpretation systems for predicting resistance to tipranavir/r and darunavir/r: results from the EuroSIDA study. Z Fox, A Cozzi-Lepri, B Clotet, J Kjaer, AN Phillips and JD Lundgren for the EuroSIDA study group
Poster P3.4/02 as pdf file 133 kb
3 Predicting the CD4 slope in patients starting cART after 1 January 1999
JD Lundgren, J Gatell, JR Bogner, K Lacombe, M Murphy, A Wiercinska-Drapalo, P Reiss, A Lazzarin, AN Phillips, A Mocroft for the EuroSIDA study group
Poster P6.11/02/BPD as pdf file 169 kb
4 Virological response to nucleos(t)ide analogues backbones initiated after virological
failure on thymidine analogues-containing treatments. A Cozzi-Lepri, AN Phillips, B Clotet, C Katlama, A Castagna, A Karlsson, B Ledergerber, B Knysz, K Zilmer, O Kirk and JD Lundgren for the EuroSIDA study group
Poster P7.4/01 as pdf file 94 kb
5 Incidence of pancreatitis amongst HIV-positive individuals, and the association with triglycerides and antiretroviral use. CJ Smith, A Mocroft, CH Olsen, F Antunes, S Staszewski, P Domingo, J Weber, E Vinogradova, H Sambattakou, JP Viard, JD Lundgren and the EuroSIDA Study Group
Poster P9.10/02 as pdf file 92 kb
6 The EuroSIDA risk score : Separate prediction for AIDS or death. JD Lundgren, B Ledergerber, B Gazzard, D Banhegyi, M Mokras, D Turner, P Domingo, G Fatkenheuer, O Kirk, A Mocroft for the EuroSIDA study group
Poster P18.4/01 as pdf file 199 kb
Oral
1 Does diabetes mellitus (DM) confer a risk of coronary heart disease (CHD) equivalent to that of prior CHD in HIV-positive individuals? S Worm, S de Wit, R Weber, C Sabin, P Reiss, W El-Sadr, A D´arminio Monforte, O Kirk, E Fontas, F Dabis, M Law, J Lundgren, N Friis-Møller for the D:A:D Study group
Abstract No. PS2/6 slides
2 Does Hepatitis C virus (HCV) genotype or viral load predict the risk of all-cause mortality of HIV/HCV coinfection? JK Rockstroh, A Mocroft, P Reiss, A D`Arminio Monteforte, M Beniowski, C Pradier, K Zilmer, M Losso, O Kirk, L Peters, B Kupfer, V Soriano on behalf of the EuroSIDA Study Group
Abstract No. PS8/2 slides
3 Epidemiological and virological characteristics of chronic hepatitis C (HCV) within the EuroSIDA observational cohort. V Soriano, A Mocroft, B Ledergerber, B Knysz, S Chaplinskas, L Peters, A Karlsson, C Katlama, M Vogel, J Rockstroh, JD Lundgren for the EuroSIDA study group.
Abstract No. PS8/1 slides
4th IAS Conference on HIV Pathogenisis, Treatment and Prevention, Sydney, July 2007
Oral
1 Higher rate of antiretroviral therapy reinitiation among HIV-HBV coinfected patients in the episodic therapy arm of the SMART study. G Dore, V Soriano, J Neuhaus, L Peters, M Puoti, J Rockstroh, M Klein, E Tedaldi, A Mocroft, B Clotet, JD Lundgren; For the SMART study group and INSIGHT
2 Opportunistic disease and mortality in patients co-infected with hepatitis C virus (HCV) and/or hepatitis B virus (HBV) in the SMART (Strategic Management of Antiretroviral Therapy) study. E Tedaldi, M Puoti, J Neuhaus, L Peters, J Rockstroh, M Klein, G Dore, A Mocroft, V Soriano, B Clotet, JD Lundgren; For the SMART study group and INSIGHT
9th Intl Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, Sydney July 2007
1 Does diabetes mellitus (DM) confer an equivalent risk of coronary heart disease (CHD) to pre-existing CHD in HIV-positive individuals? SW Worm, S De Wit, R Weber, CA Sabin, P Reiss, W El-Sadr, A D‘Arminio Monforte, O Kirk, E Fontas, F Dabis, MG Law, JD Lundgren and N Friis-Møller on behalf of the D:A:D study group
Abstract No 0-09
XVI International HIV Drug Resistance Workshop, Barbados, June 2007
1 Prediction of phenotypic susceptibility to the three major HIV drug classes from physiochemical properties of the primary enzymatic structure using artificial neural networks (ANNs). J Kjær, L Høj, Z Fox and JD Lundgren
Poster as pdf file 585 kb
2 Association between Resistance and CD4 Count Change in Patients on ART with Ongoing Viraemia. ZV Fox, AM Geretti, B Clotet, A Cozzi-Lepri, T Hill, H Green, CA Sabin, B Ledergerber, JD Lundgren and AN Phillips for the UK Collaborative Group on HIV Drug Resistance, EuroSIDA and UK CHIC Studies
Poster as pdf file 153 kb
3 Rate of accumulation of thymidine analogue mutations in patients left on virologically failing regimens containing zidovudine or stavudine. A Cozzi-Lepri, AN Phillips, J Martinez-Picado, A d’Arminio Monforte, C Katlama, A-B Eg Hansen, A Horban, J Bruun, B Clotet and J Lundgren for the EuroSIDA study group
Poster as pdf file 86 kb
4 Proof-of-Principle Evaluation of Predictive Performance for Therapy Outcome of Baseline Estimated Fitness and Genetic Barrier towards Resistance in a Clinical Cohort of HIV-1 Treated Patients. K Deforche, A Cozzi-Lepri, K Theys, B Clotet, R Camacho, J Kjaer, K Van Laethem, AN Phillips, Y Moreau, JD Lundgren and A-M Vandamme for the EuroSIDA study Group.
Poster as pdf file 155kb
5th European HIV Drug Resistance Workshop, Cascais, March, 2007
Poster
1 Prediction of phenotypic susceptibility to seven protease inhibitors from chemical and structural descriptors of the protease gene’s amino acid sequence using artificial neural networks. J Kjær, L Høj, Z Fox and JD Lundgren
Poster as pdf file 738 kb
14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, February 2007
Oral
1 HIV-induced immunodeficiency and risk of fatal AIDS-defining and Non-AIDS-defining malignancies: Results from the D:A:D Study Group. A D´Arminio Monforte, D Abrams C Pradier R Weber, F Bonnet, S De Wit, N Friis-Møller, A Phillips, C Sabin, JD Lundgren, and the D:A:D Study Group.
Abstract No. 84
Posters
1 Predicting the risk of coronary heart disease (CHD) in HIV-infected patients: The D:A:D CHD risk equation. N Friis-Møller, R Thiébaut, P Reiss, W El-Sadr, R Weber, A D´Arminio Monforte, E Fontas, SW Worm, O Kirk, A Phillips, CA Sabin, JD Lundgren, M Law, and the D:A:D Study Group.
Poster 808 as pdf file 191 KB
2 Presence of the metabolic syndrome (MS) is not a better predictor of cardiovascular disease (CVD) that the sum of its components; Data from the D:A:D study. SW Worm, CA Sabin, P Reiss, W El-Sadr, A D´Arminio Monforte, C Pradier, R Thiebaut, M Law, M Rickenback, S de Wit, JD Lundgren, N Friis-Møller and the D:A:D Study Group
Poster 815 as pdf file 113 KB
3 Underutilization of recommended interventions for prevention of cardiovascular (CV) disease in HIV-infected patients with established CV disease or diabetes. CA Sabin, R Weber, F Dabis, P Reiss, S de Wit, W El-Sadr, A D´Arminio Monforte, M Law, O Kirk, SW Worm , N Friis-Møller, JD Lundgren, and the D:A:D Study Group.
Poster 816 as pdf file 118 KB
4 Detection of chronic renal failure (CRF) amon HIV-patients within the EuroSIDA Study. A Mocroft, O Kirk, J Gatell, P Reiss, P Gargalianos, K Zilmer, M Beniowski, JP Viard, S Staszewski, JD Lundgren for the EuroSIDA Study Group.
Poster 828 as pdf file 106 KB
5 Normalisation of CD4 count in HIV-infected patients with maximal virological suppression (<50 copies/ml) taking combination antiretroviral therapy. A Mocroft, AN Phillips, J Gatell, B Ledergerber, M Fisher, N Clumeck, M Losso, A Lazzarin, G Fätkenheuer, JD Lundgren for the EuroSIDA Study Group
Poster 519 as pdf file 100 KB
6 Predicted risk of coronary heart disease (CHD) with Tipranavir exposure compared to conventional PI in the RESIST trial. N Friis-Møller, M Kraft, H Valdez, D Hall, and JD Lundgren.
Poster 809 as pdf file 122 KB
2006
The 8th International Congress on Drug Therapy in HIV Infection, Glasgow, November 2006
Oral Presentations
1 Relationship between use of stavudine and diabetes mellitus. S. de Wit, CA Sabin, R Weber, SW Worm, P Reiss, R Thiebaut, W El-Sadr, A D´Arminio Monforte, E Fontas, MG Law, AN Phillips, N Friis-Møller, JD Lundgren for the DAD study Group.
Slides as pdf file 60 kb>
2 Effect of interventions to improve dyslipidaemia. M de Valk, N Friis-Møller, CA Sabin, F Dabis, A d´Arminio Monforte, R Weber, S Worm, W El-Sadr, S de Wit, C Pradier, O Kirk, M Law, AN Phillips, JD Lundgren, P Reiss for the DAD study group
Slides as pdf file 96 kb
3 Final safety and efficacy analysis of a randomised pilot study evaluating early versus late switch from efavirenz to nevirapine as part of HAART: the BI Switch Study. M Youle, U B Dragsted, D Podlekareva, C Smith, A Caroll, F Turner, M Johnson
Poster Presentations
1 Comparison of single and boosted-protease-inhibitor (PI) versus non-nucleoside reverse transcriptase inhibitor (NNRTI) containing regimens in previously antiretroviral naïve patients. A Mocroft, O Kirk, A Horban, N CLumeck, HJ Stellbrink, A d´Arminio, K Zilmer, J Gatell, AN Phillips, JD Lundgren for the EuroSIDA study group.
Poster as pdf file 138 kb
2 Abacavir hypersensitivity reaction in EuroSIDA. W Bannister, N Friis-Møller, A Mocroft, JP Viard, J van Lunzen, O Kirk, P Garglianos, D Banhegyi, A Chiesi, J Lundgren for the EuroSIDA study group.
Poster as pdf file 673 kb
3 The Metabolic Syndrome at baseline in the D:A:D Study. S Worm, C Sabin, W El-Sadr, P Reiss, A Monforte, M Rickenbach, R Thiebaut, S de Wit, E Fontas, M Law, O Kirk, J Lundgren, N Friis-Møller for the DAD study
Poster as pdf file 129 kb
The XVI International AIDS Conference, Toronto, August 2006
Oral Presentations
1 Progression of HIV-related disease or death (POD) in the randomised SMART study:why was the risk of POD greater in the CD4 guided ((re)-initiate ART at CD4<250 cells/µL) drug conservation (DC) vs the virological suppression(VS) arm? Jens D. Lundgren on behalf of the SMART study group.
2 Risk of discontinuation of nevirapine due to toxicitites in antiretroviral naive and experienced patients with high and low CD4 counts. A Mocroft, J Rockstroh, J Gasiorowski, F Antunes, G Panos, A d´Arminio Monforte, A Rakhmanova,, AN Phillips, JD Lundgren for the EuroSIDA study group.
Slides as pdf file 153 KB
3 All naïve patients are not equal: when and how to start HAART. JD Lundgren
Posters
1 The ability of four genotypic resistance algorithmis for predicting HIV-RNA responses 4-24 weeks after initiating a boosted PI-containing regimen. Z Fox, J Kjær, AN Phillips, L Ruiz, B Clotet, S Staszewski, C Holkmann Olsen, A Horban, B Ledergerber, JD Lundgren for the EuroSIDA study group.
Poster as pdf file 137 KB
2 Genotypic resistance profile before initiation of cART and association with virological and clinical outcome in EuroSIDA. WP Bannister, AN Phillips, B Clotet, P Reiss, B Ledergerber, A Lazzarin, C Katlama, A Cozzi-Lepri, L Ruiz, JD Lundgren for the EuroSIDA study group.
Poster as pdf file 85 KB
3 Short term clinical disease progression in HIV-1 positive patients taking combination antiretroviral therapy: The EuroSIDA risk-score. A Mocroft, B Ledergerber, K Zilmer, O Kirk, B Hirschel, JP Viard, P Reiss, P Francioli, A Lazzarin, L Machala, AN Phillips, JD Lundgren for the EuroSIDA study and the Swiss HIV Cohort study.
Poster as pdf file 759 KB
4th European Drug Resistance Workshop, Monte Carlo, March 2006
1 The ability of four genotypic resistance algorithms to predict HIV-RNA responses to boosted PI-containing regimens after 4 and 12 weeks follow-up. Z Fox, M Gisslen, B Gazzard, J Kjær, H Nielsen, M Youle, I Cassetti, AN Phillips, UB Dragsted, and JD Lundgren on behalf of the MaxCmin1, MaxCmin2 and COLATE trial groups
Poster as pdf-file 636 KB
13th Conference on Retroviruses and Opportunistic Infections, Denver, February 2006
Oral presentation
1 Exposure to PI and NNRTI and risk of myocardial infaction: Results from the D:A:D Study. N Friis-Møller, P Reiss, W El-Sadr, A D´Arminio Monforte, R Thiebaut, S De Wit, R Weber, E Fontas, M Law, A Phillips, O Kirk, CA Sabin, JD Lundgren, and the D:A:D Study group
Posters
1 Mutation at reverse transcriptase codon 214 is antagonist to thymidine analogue mutations type 2 profiles and predicts virological response to thymidine analogue-containing cART regimens only if TAM type 1 profiles concomitantly detected. A Cozzi-Lepri, L Ruiz, F Ceccherini-Silberstein, A Mocroft, A Phillips, J Gatell, B Ledergerber, P Reiss, B Clotet, JD Lundgren and the EuroSIDA Study group.
Poster as pdf file 966 KB
2 Factors associated with the development of opportunistic infections in HIV-1-infected adults with high CD4 cell counts in the EuroSIDA study. D Podlekareva, U Dragsted, A Mocroft, B Ledergerber, M Beniowski, A Lazzarin, J Weber, N Clumeck, A Phillips, JD Lundgren and the EuroSIDA Study group.
Poster as pdf file 76 KB
3 Exposure to antiretroviral therapy and the risk of liver-related death: Is there an association? Results from the D:A:D Study. R Weber, C Sabin, N Friis-Møller, A D'Arminio Monforte, P Reiss, W El-Sadr, F Dabis, M Law, C Pradier, S De Wit, O Kirk, A Phillips, JD. Lundgren; On behalf of the D:A:D Study Group
Poster as pdf file100 KB